

BRADLEY L. CAMPBELL

President and Chief Operating Officer

Bradley L. Campbell is the President and Chief Operating Officer of Amicus (NASDAQ: FOLD) and is also a member of the Board of Directors. He brings over 15 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global commercial organization responsible for the strategy, design and execution of the launch of Galafold™. He also oversees the Technical Operations, Market Access, and Program Management functions.

Prior to Amicus, Mr. Campbell spent time in various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates.

Mr. Campbell is active with various Boards and philanthropic organizations. He currently serves as a member of the Board of Directors of Progenics Pharmaceuticals (NASDAQ: PGNX), a pharmaceutical company focused developing medicines to identify, target and treat cancer. He is also a member of the BioNJ Board and of the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. Bradley received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.

